Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis
- PMID: 30001240
- DOI: 10.1097/PAS.0000000000001125
Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis
Abstract
Low-grade osteosarcoma (LGOS) encompasses low-grade central osteosarcoma (LGCOS) and parosteal osteosarcoma (POS). LGOSs are characterized by a supernumerary ring and giant rod chromosomes containing the 12q13-15 amplicon. The fibroblast growth factor receptor substrate 2 (FRS2) gene is located close to MDM2 and CDK4. Recent studies identified consistent amplification of FRS2 gene in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma. The aim of this study was to evaluate the frequency of FRS2 amplification and its relationship with the clinicopathologic features of LGOSs. The amplification of FRS2 and MDM2 genes were analyzed by fluorescence in situ hybridization using 22 LGOSs (3 LGCOSs, 14 classic POSs, and 5 dedifferentiated POSs) and 85 control samples of bone and soft tissue. The clinicopathologic features of the 22 LGOSs were described. Amplification of FRS2 was detected in 21/22 (95%) of the LGOSs, including 3 (100%) LGCOSs and 18 (95%) POSs. All 22 LGOSs showed MDM2 amplification (100%). The only MDM2/FRS2 LGOS was dedifferentiated POS (the dedifferentiated component was conventional osteosarcoma). In the control group, all of the atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcomas (DDLs) (10/10, 100%) were FRS2-amplified, whereas the remaining 75 control cases were FRS2-nonamplified. These findings indicate that the FRS2 gene is consistently amplified in classic and dedifferentiated LGOSs but not in their histologic mimics. These results offer another avenue for investigating the biology of LGOSs. Whether FRS2-nonamplified tumors exhibit unusual clinicopathologic features needs further investigation. Some so-called "high-grade osteosarcomas harboring 12q13-15 amplification" may be unrecognized dedifferentiated LGOSs.
Similar articles
-
Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.Histopathology. 2018 Jun;72(7):1145-1155. doi: 10.1111/his.13473. Epub 2018 Mar 7. Histopathology. 2018. PMID: 29368794
-
Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.Diagn Pathol. 2021 Oct 25;16(1):96. doi: 10.1186/s13000-021-01161-9. Diagn Pathol. 2021. PMID: 34696768 Free PMC article.
-
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.Genes Chromosomes Cancer. 2011 Nov;50(11):849-58. doi: 10.1002/gcc.20906. Epub 2011 Jul 26. Genes Chromosomes Cancer. 2011. PMID: 21793095
-
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.Crit Rev Oncol Hematol. 2020 Sep;153:103029. doi: 10.1016/j.critrevonc.2020.103029. Epub 2020 Jun 18. Crit Rev Oncol Hematol. 2020. PMID: 32593094 Review.
-
[From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors].Bull Cancer. 2004 Apr;91(4):317-23. Bull Cancer. 2004. PMID: 15242313 Review. French.
Cited by
-
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma.NPJ Genom Med. 2024 Sep 25;9(1):42. doi: 10.1038/s41525-024-00430-y. NPJ Genom Med. 2024. PMID: 39322633 Free PMC article.
-
Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications.Cancers (Basel). 2024 Jan 19;16(2):432. doi: 10.3390/cancers16020432. Cancers (Basel). 2024. PMID: 38275873 Free PMC article. Review.
-
Case Report: Primary low-grade dedifferentiated liposarcoma of the urinary bladder with molecular confirmation.Front Oncol. 2023 Oct 10;13:1221027. doi: 10.3389/fonc.2023.1221027. eCollection 2023. Front Oncol. 2023. PMID: 37881487 Free PMC article.
-
The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors.Int J Mol Sci. 2023 Mar 21;24(6):5934. doi: 10.3390/ijms24065934. Int J Mol Sci. 2023. PMID: 36983010 Free PMC article. Review.
-
Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry.Virchows Arch. 2023 Jun;482(6):999-1010. doi: 10.1007/s00428-023-03530-9. Epub 2023 Mar 28. Virchows Arch. 2023. PMID: 36977943
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
